Highlight
- Unselected germline multigene testing in ovarian carcinoma identifies pathogenic/likely-pathogenic variants in nearly 30% of patients.
- BRCA1/2 mutations remain predominant but significant detection extends beyond these genes, underscoring broader genetic assessment.
- Germline and somatic BRCA testing show high concordance, facilitating complementary diagnostic strategies.
- Optimized testing workflows balancing germline-first and tumor-first approaches enhance detection rates and reduce assay burden.
Study Background
